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Available online 15 June 2016Mammalian cells maintain the glycerophospholipid (GPL) compositions of their membranes nearly constant. To
achieve this, GPL synthesis and degradationmust be coordinated. There is strong evidence that A-type phospho-
lipases (PLAs) are key players in homeostatic degradation of GPLs, but the identities of the PLAs involvedhave not
been established. However, some members of the Patatin-like phospholipase domain-containing proteins
(PNPLAs) have been implicated. Accordingly, we knocked down all the PNPLAs significantly expressed
in human HeLa cells using RNA interference and then determined whether the turnover of the major
glycerophospholipids is affected by using mass spectrometry and metabolic labeling with stable isotope-
labeled precursors. Knockdown of PNPLA9, PNPLA6 or PNPLA4 significantly (30–50%) reduced the turnover of
phosphatidylcholine, −ethanolamine and –serine. In a notable contrast, turnover of phosphatidylinositol was
not significantly affected by the knockdown of any PNPLA. Depletion of PNPLA9 and PNPLA4 also inhibited G0/
G1 to S cell cycle progression, which could thus be regulated by GPL turnover. These results strongly suggest
that PNPLA9, -6 and -4play a key role inGPL turnover and homeostasis in human cells. A hypotheticalmodel sug-
gesting how these enzymes could recognize the relative concentration of the different GPLs is proposed.






Glycerophospholipids (GPLs) form the lipid bilayer of all biological
membranes and are also intimately involved in signal transduction,
regulation of membrane trafficking and numerous other cellular
phenomena [1]. Higher eukaryotesmaintain the relative concentrations
of the GPL classes within narrow limits [2,3], presumably because such
homeostasis is vital for the organism. Consistently, hardly any human
diseases exhibiting a significant deviation from the normal GPL compo-
sition exist, and deletion of a gene essential for the synthesis of a GPL is
lethal in mice [4]. Yet, most GPLs are synthesized via more than one
pathway (or enzyme isoform) supporting the notion that maintenance
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k.homeostasis are biosynthesis, remodeling (i.e., exchange of a fatty acid
residue) and degradation. Albeit the details of GPL homeostasis in
mammals are still poorly understood [2], it is obvious that the
biosynthesis and degradation of GPLs must be tightly coordinated [5].
Compelling evidence for this comes from studies where the synthesis
of a GPL was boosted by over-expressing a rate-limiting synthetic en-
zyme in cultured cells. Thus the overexpression of CTP:phosphocholine
cytidylyltransferase boosted phosphatidylcholine (PC) synthesis several
fold but, remarkably, the PC content of the cells was hardly increased
[6–9]. Instead, the concentration of glycerophosphocholine (GPC), a
deacylation product of PC, increased greatly. Analogously, boosting of
the synthesis of phosphatidylethanolamine (PE) or phosphatidylserine
(PS) did not significantly increase the cellular content of the respective
GPL but its degradation increased in parallel [10,11]. Conversely, when
the synthesis of a GPL was inhibited, its turnover decreased in propor-
tion [12,13]. Obviously, mammalian cells must contain homeostatic
phospholipases which “sense” the prevailing GPL composition and
selectively degrade the GPL present in excess [2].
While the specific phospholipases involved in homeostatic degrada-
tion of GPLs have not been identified yet, certain PNPLA species have
been implicated [2,8,14–17]. PNPLAs (a.k.a. Group VI Ca2+-independent
phospholipases A or iPLA2s) comprise a family of mammalian lipid
hydrolases with 9 members [18,19]. Some PNPLAs act as phospholipases
hydrolyzing the sn1 or sn2 ester bond of an intact GPL or a lyso-GPL [17],
while others mainly hydrolyze triacylglycerols in vitro [18,20]. Several
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implicated in various biological processes including GPL acyl chain re-
modeling [14,21,22], release of polyunsaturated fatty acids fromneuronal
GPLs [23], removal of oxidized acyl chains frommitochondrial GPLs [24],
stimulation of insulin secretion [25], cell growth [26], development of
non-alcoholic fatty liver disease [27] as well as numerous other cellular
processes and disorders (reviewed in [17,19,28]).
Regarding GPL homeostasis, overproduction of PC in Chinese ham-
ster ovary cells greatly stimulated the production of PNPLA9 (a.k.a.
iPLA2β or Group VIA Ca2+-independent PLA2) as well as GPC [9], thus
implying that PNPLA9 could be responsible for the degradation of the
excess PCs. However, studies where PNPLA9 was overexpressed in
COS-7 cells did not support this possibility [29]. Also PNPLA6 (a.k.a.
iPLA2δ or NTE) has been implicated in GPL homeostasis [16], but this
has not been firmly established.
Notably, several studies addressing the role of PNPLAs in GPL ho-
meostasis have employed pharmacological inhibitors [2,17]. Such stud-
ies are, however, inconclusive since the inhibitors used are not selective
for the targeted PLA [28]. In addition, in nearly all studies addressing the
role of PLAs in GPL homeostasis the steady-state GPL composition of
cells or tissues was determined. This approach can be is problematic,
since any (possible) effect onGPL turnover is likely to remain unnoticed
due to the compensatory decrease of biosynthesis.
In this study, we first determined which PNPLAs are significantly
expressed in HeLa cells by using RT-qPCR. Each PNPLA was then
knocked down using RNA interference and the turnover of the major
GPLs was determined by using deuterium-labeled GPL precursors and
mass spectrometry. Notably, the knockdown of PNPLA4, PNPLA6 or
PNPLA9 inhibited the turnover of PC, PE or PS markedly (by 30–50%).
In contrast, the knockdown of the other PNPLAs had no detectable ef-
fect. Accordingly, these results provide strong evidence for that
PNPLA4, PNPLA6 and PNPLA9 are important players in GPL homeostasis
in mammalian cells.
2. Materials and methods
2.1. Chemicals and reagents
Culture media and reagents were obtained from Invitrogen,
D9-choline, D4-choline, D3-L-serine and D4-ethanolamine from
Cambridge Isotope Laboratories (Andover, MA), D6-myo-inositol from
CDN Isotopes (Quebec, Canada), 35S-methionine from Perkin Elmer,
phospholipase D (Streptomyces sp.), formic acid, ammonium formate
and ammonium hydroxide from Sigma. All solvents (LC-MS grade)
were from Fisher Scientific (Finland). Phospholipid standards were
purchased from Avanti Polar Lipids (Alabaster, AL) or were synthesized
as previously [30,31]. Their purities were confirmed bymass spectrom-
etry and their concentrations were determined based on phosphate
analysis [32].
2.2. Cell culture and RNA interference
HeLa cells were cultured in DMEM containing 10% fetal bovine
serum, 100 units/ml penicillin and 100 μg/ml streptomycin under 5%
CO2 at 37 °C. RNA interference was employed to knockdown the
mRNAs of specific PNPLAs. The double stranded siRNA's used are listed
in Supplemental Table S1. Each siRNA was used at the lowest effective
concentration which varied from 2 to 10 nM. Cells grown to ~50%
confluency on 35 or 60 mm dishes were transfected with a siRNA by
using the Lipofectamine™ RNAiMAX reagent (Invitrogen) according to
manufacturer's instructions up to 72 h.
2.3. RNA isolation and RT-qPCR
Total RNAwas extracted from siRNA-treated cells byMachery-Nagel
NucleoSpin® RNA II Kit (Biotop Oy, Finland) according to themanufacturer's instructions. 2 μg of RNA was transcribed into cDNA
using the RevertAid™ H Minus Reverse Transcriptase (Fermentas) and
random hexameric primers. The qPCR reactions were carried out on
Bio-Rad C1000™ Thermal Cycler in 20 μl using 5 μl of cDNA diluted by
1:6–1:20, 300 nM primers and the FastStart Universal SYBR Green
Master-mix (Roche, Finland). The amplification (35–40 cycles)was car-
ried out at 95 °C for 15 s, then at 55 °C for 30 s following 60 °C for 30 s.
The data were analyzed by the CFX Manager™ 2.0 software. The qPCR
primers (cf. Supplemental Table S2) were from Applied Biosystems or
Oligomer (Helsinki, Finland).
2.4. Metabolic labeling
After 72 h of transfection the cells were washed with PBS and
then incubated in DMEM containing 10% FBS, 1 mM hydroxylamine,
D9-choline (100 μg/ml), D4-ethanolamine (100 μg/ml, adjusted to
pH 7.0 by acetic acid), D3-L-serine (300 μg/ml) and D6-myo-inositol
(100 μg/ml). In the pulse-chase experiments the cells were incubated
in the labeling medium for 4 or 24 h, washed thrice with DMEM and
then incubated in DMEM containing 10% FBS, 1 mM hydroxylamine,
unlabeled choline (500 μg/ml), ethanolamine (500 μg/ml), L-serine
(1000 μg/ml) and myo-inositol (500 μg/ml) up to 24 h. After washing
thrice with PBS, the cells were scraped into 2 ml of ice-cold water, the
suspensionwas vortexed and aliquots werewithdrawn for protein con-
centration determination. The remaining suspension was mixed with
3 ml of ice-cold methanol and stored at −20 °C. To assess the effect of
RNAi on the rate of protein synthesis, the cells were transfected with a
siRNA as above (cf. Section 2.2) and then [35S]-methionine (10 μCi/ml)
was added to the medium. After incubation for up to 3 h, the cells
were washed thrice with PBS, scraped into 2 ml of PBS, pelleted by
centrifugation and suspended in RIPA lysis buffer (Thermo Scientific).
Aliquots were withdrawn for protein concentration determination and
the remaining sample was mixed with Optisafe scintillation fluid to
determine its radioactivity by scintillation counting.
2.5. Lipid analysis
The lipids were extracted [33] with added internal standards and
after evaporation of the solvent the lipids were dissolved in methanol/
chloroform (2:1, v/v) and stored at −20 °C before the analysis with
LC-MS. The lipids were separated on a Waters Acquity UPLC system
equipped with an Acquity BEH-C18 1.0 × 150 mm column using a sol-
vent gradient described previously [34]. The eluent was infused to the
ESI source of aWaters QuattroMicro triple–quadrupolemass spectrom-
eter operated in the positive ion mode and the individual lipid species
were detectedusing selective reactionmonitoring (SRM). The precursor
ionswere [M+H]+ for PC, SM, PE, PS and [M+NH4]+ for PI. The prod-
uct ion was phosphocholine for PC or SM and diacylglycerol for PE, PS
and PI. Triacylglycerols (TAG) were detected as [M + NH4]+-ions. The
concentrations of the individual lipid species were determined from
the SRM or ion chromatograms using the QuanLynx and TargetLynx
software tools (Waters). To assess GPL turnover rates the labeled-to-
unlabeled-ratio for each individual GPL-class was plotted against
chase time and the label half-time was calculated from fits of an expo-
nential decay model to the data points using OriginPro 8.5 (OriginLab,
MA).
2.6. Analysis of water-soluble lipid metabolites
To determine the labeling of thewater-soluble choline, serine or eth-
anolamine metabolites the cells were incubated with deuterium-
labeled choline, serine and ethanolamine as above (cf. Section 2.4).
They were then washed with PBS and subjected to lipid extraction
[33] after addition of the D4-choline, propanolamine and threonine
standards. The upper phase was recovered, evaporated to dryness
under a nitrogen stream and the residue was reconstituted in
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rectly by LC-MS [35], while the ethanolamine and serine metabolites
were first converted to dansylated derivatives [36] which were then
quantified with LC-MS using SRM [34].
2.7. Cell cycle analysis
The cells were transfected with a siRNA for 72 h as above (cf.
Section 2.2), collected and the level of PNPLA knockdown was deter-
mined with RT-qPCR. The cells were fixed with ethanol and the DNA
was stained using the FxCycle™ PI/RNase staining solution (Life Tech-
nologies) according to the manufacturer's protocol. The cells were
then analyzed on a BD Accuri™ C6 flow cytometer and the data were
processed with the BD Accuri™ C6 1.0 software. Cell doublets were
eliminated using the side scatter pulse height versus side scatter pulse
area dot plot. Expression of the proliferation marker Ki-67 (gene
MKI67) was determined using RT-qPCR [37].
2.8. Other assays
Publishedmethodswere used to quantify protein [38] and total lipid
phosphorus [32].
3. Results
3.1. Knockdown of the PNPLAs expressed in HeLa cells
The mammalian PNPLA family consists of 9 members i.e.,
PNPLA1 - PNPLA9 [18]. By using RT-qPCR we found that in HeLa
cells PNPLAs 2, 3, 4, 6, 8 and 9 are expressed at a significant level
while PNPLAs 1, 5 and -7 were not detectable (Supplemental Fig. S1).
Accordingly, we targeted each of the 6 significantly expressed PNPLAs
with a specific siRNA for 72 h and then quantified the respective
mRNAs with RT-qPCR. The targeted mRNA was reduced by 70–95% de-
pending on the PNPLA (Supplemental Table S3, Fig. S2). The PNPLA9
and PNPLA6 proteins were also markedly reduced in the respective
cells as determined by Western blotting (Supplemental Figs. S3 & S4).
The levels of the other PNPLA proteins could not be determined
since suitable antibodies were not available. We also measured how
depletion of a PNPLA affected the expression of non-targeted PNPLAs
(Supplemental Fig. S2). Modest fluctuations in the levels of the non-
targeted PNPLAmRNAswere observed and thus possible compensatory
effects cannot be completely excluded.
3.2. Effect of PNPLA depletion on the cellular lipid composition
HeLa cells were treated with a control siRNA or siRNA targeting a
PNPLA for 72 h (cf. Section 2.2 Materials and methods) and the protein,
lipid phosphate, TAG and cholesterol contents of the cells were mea-
sured. A modest (~15%) increase in the lipid phosphate was observed
in the cells depleted of PNPLA2, -6 or -9, while no change was detectedTable 1
Lipid class compositions of PNPLA-depleted HeLa cells. HeLa cells were treated with a control
growth medium for 24 h. The cellular lipid and protein contents were then quantified as desc
experiments ± SD.
nmol/mg protein mol%
Lipid phosphorus TAG PC PE PE
CTRL 135 ± 7 3.7 ± 0.3 55.5 ± 3.1 16.5 ± 0.3 4.
PNPLA2 164 ± 16 12.1 ± 1.6 54.6 ± 0.7 17.4 ± 1.5 4.
PNPLA3 145 ± 3 3.6 ± 0.6 55.1 ± 2.8 14.9 ± 2.7 3.
PNPLA4 148 ± 3 11.5 ± 2.7 55.2 ± 2.0 15.8 ± 0.8 4.
PNPLA6 156 ± 5 4.5 ± 1.3 54.4 ± 0.1 16.4 ± 0.9 3.
PNPLA8 138 ± 8 3.8 ± 0.3 56.1 ± 2.0 15.2 ± 2.6 4.
PNPLA9 153 ± 8 8.0 ± 2.0 54.1 ± 3.3 20.3 ± 1.5 4.in those depleted of PNPLA4, -3 or -8 (Table 1). The phospholipid class
(Table 1) or the phospholipid molecular species (data not shown) com-
positions of the cells were only slightly affected by the knockdown of
each PNPLA. However, the knockdown of PNPLA6 or -9 diminished
the concentration of phosphatidic acid (PA) by ~50% while the knock-
down of PNPLA2, -3 or -4 had a lesser effect on this lipid. Depletion of
PNPLA6 also caused ~2.5-fold increase in the lyso-PC content of the
cells. In the cells depleted of PNPLA2, -4 or -9 TAG increased by approx.
3-, 3- or 2-fold, respectively. In summary, the depletion of each PNPLA
had only a minor effect on the membrane lipid composition of HeLa
cells, but the TAG content of the cells depleted of PNPLA2, -4 or -9 in-
creased markedly.3.3. Effect of PNPLA depletion on phospholipid turnover
Although the depletion of none of the PNPLAs significantly altered
the GPL compositions of HeLa cells, the turnover of GPLs could have
been affected because the synthesis and degradation are coordinated
(cf. Section 1 Introduction). To test this, HeLa cells were pretreated
with a specific siRNA for 72 h and then incubated with deuterium-
labeled choline, ethanolamine, serine and inositol for 24 h, washed
and chased in a medium containing the respective unlabeled precur-
sors. Hydroxylamine (1 mM), an inhibitor of PS decarboxylase, was
added to the media to prevent decarboxylation of PS to PE, thus
avoiding overlapping MS signals from the serine- and ethanolamine-
labeled PE species. After lipid extraction, GPLs were quantified by LC-
MS and the labeled/unlabeled ratio was determined for the major GPL
classes and sphingomyelin vs. the chase time (Fig. 1). First, in the cells
depleted of PNPLA9 the label was chased from PC much more slowly
(half-time 17.5 h) than from the control cells (half-time 8.5 h) (Fig. 1;
Table 2). Second, the turnover of the diacyl and plasmalogen PE classes
was also markedly reduced (Fig. 1; Table 2). The labeling of these GPLs
still increased during the early chase, most probably because the pool of
cellular (phospho)ethanolamine is relatively large and thus only slowly
diluted by cold (phospho)ethanolamine. Third, the turnover of PS was
nearly abolished when PNPLA9 was knocked down (Fig. 1). Fourth, in
a sharp contrast to the other GPLs, the turnover of PIwas not significant-
ly influenced (Fig. 1). The turnover rate of SM could not be measured
since its labeling continued to increase until the end of the chase,
most probably due to that SM receives its head group from PC.
The turnover data obtained after the knockdown of the other
PNPLAs is summarized in Table 2. The knockdown of PNPLA6 reduced
the turnover of PC, PE and PS similarly to PNPLA9, while in the
PNPLA4-depleted cells the turnover of these GPLs was somewhat less
affected. In contrast to those PNPLAs, depletion of PNPLA8 had only a
small effect on the turnover of PC, PE and PS, and no effect was detected
upon the depletion PNPLA2 or PNPLA3. Turnover of PI was not affected
in any of the knockdown cells (Table 2). Comparable results were ob-
tained when a shorter time of labeling (4 h) was employed (data not
shown).siRNA or siRNA targeting the indicated PNPLA for 72 h, washed and then incubated in the
ribed under Materials and Methods (Sections 2.5 & 2.8). Data are mean of 3 independent
p PS PI PA LPC SM
3 ± 0.3 6.2 ± 1.2 4.7 ± 0.6 4.3 ± 0.4 1.5 ± 0.2 6.8 ± 0.3
9 ± 0.4 6.6 ± 0.9 4.8 ± 0.5 2.4 ± 0.7 1.5 ± 0.1 7.7 ± 0.4
9 ± 0.3 8.0 ± 0.2 4.8 ± 1.4 2.9 ± 0.3 1.8 ± 0.5 8.3 ± 0.8
1 ± 0.4 8.3 ± 0.5 5.4 ± 1.3 3.0 ± 0.5 1.4 ± 0.2 6.4 ± 0.5
8 ± 0.8 6.3 ± 0.4 4.8 ± 0.3 1.8 ± 0.1 3.6 ± 0.2 8.6 ± 1.4
3 ± 0.6 6.5 ± 0.9 4.6 ± 0.4 3.8 ± 0.2 1.7 ± 0.1 7.6 ± 0.4
0 ± 0.3 7.4 ± 0.8 5.0 ± 1.2 1.6 ± 0.3 1.4 ± 0.1 6.0 ± 0.5
Fig. 1. Effect of PNPLA9 depletion on GPL head group turnover. HeLa cells were treated with a non-silencing siRNA (black squares) or a siRNA targeting PNPLA9 (red circles) for 72 h and
were then incubated in amedium containing D9-choline, D4-ethanolamine, D3-L-serine, D6-myo-inositol and hydroxylamine for 24 h. The cells were thenwashed and chased in amedium
containing the respective unlabeled precursors. The labeled and unlabeled lipids were quantified by LC-MS as detailed under Materials andmethods. The data are mean of 3 independent
experiments ± SD.
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Complete deacylation of PC and PE leads to formation of
glycerophosphocholine (GPC) or –ethanolamine (GPE), respectively.
Since previous reports indicated that pharmacological (nonspecific) in-
hibition of PNPLAs reduces the levels of these metabolites [8,39], we
assessed whether the depletion of PNPLA9, -6 or -4 would reduce the
concentrations and/or labeling of GPC and GPE. HeLa cells were
transfected with a siRNA for 72 h, incubated with deuterated choline
and ethanolamine for 24 h and the labeled and unlabeled GPC and
GPE were determined by LC-MS. The total GPC content of the control,
PNPLA9, -6 or -4 siRNA-treated cells were 23.2 ± 2.1, 16.8 ± 0.8,
16.2±3.3 and15.1±2.2 nmol/mgprotein, respectively. Thus depletion
of PNPLA9, -6 or -4 reduced the concentration of GPC by30–35%. Consis-
tently, the labeling of GPC in the PNPLA9 or PNPLA6-depleted cells wasTable 2
Effect of PNPLA9 depletion on GPL head group turnover. HeLa cells were treated with a
control siRNA or a siRNA targeting the indicated PNPLA for 72 h and then the turnover
of the different GPLs were determined as detailed under Materials and methods. Data
are mean of 3–5 independent experiments ± SD.
Label half-time (h)
PC PE PEp PS PI
CTRL 8.5 ± 0.9 13.6 ± 2.1 16.3 ± 2.8 18.4 ± 2.2 6.8 ± 0.8
PNPLA2 9.2 ± 1.1 14.3 ± 1.4 16.6 ± 2.4 19.2 ± 2.4 5.9 ± 1.1
PNPLA3 9.0 ± 1.4 13.1 ± 2.0 15.7 ± 1.8 20.1 ± 2.2 6.1 ± 1.3
PNPLA4 15.7 ± 1.4 17.8 ± 2.6 25.3 ± 3.7 43.2 ± 3.2 6.4 ± 1.2
PNPLA6 17.4 ± 4.2 24.1 ± 4.4 27.7 ± 3.2 44.5 ± 4.5 7.9 ± 1.1
PNPLA8 10.2 ± 1.1 17.5 ± 2.7 18.3 ± 1.9 33.4 ± 3.3 6.6 ± 0.5
PNPLA9 17.6 ± 2.9 19.8 ± 3.2 29.8 ± 4.4 54.2 ± 13.4 8.8 ± 1.3reduced by 20–25% (Supplemental Fig. S5). Also the GPE content of the
knockdown cells wasmarkedly reduced. i.e., the GPE content of the con-
trol cells and PNPLA9, -6 or -4 siRNA-treated cells were 0.90 ± 0.11,
0.45±0.13, 0.63±0.05 and 0.36±0.21 nmol/mgprotein, respectively.
The glycerophosphoserine content of the cells was too low formeaning-
ful analyses. In summary, these results are consistent with involvement
of PNPLA4, -6 and -9 in the deacylation of PC and PE.
3.5. Effect of PNPLA depletion on GPL synthesis
As shown in Fig. 1., the labeling of PC, PE, PEp, PS or SM was signifi-
cantly reduced in the cells depleted of PNPLA9 after a 24 h pulse, indi-
cating that the synthesis of those GPLs was markedly reduced in the
knockdown cells. Therefore, the labeling of those lipids in the knock-
down cells was investigated (Fig. 2). Besides PNPLA9, the depletion of
PNPLA4, -6 or -8 significantly reduced the labeling of the GPLs, while
the knockdown of PNPLA2 and -3 had no effect. As expected, the label-
ing of PI was not affected by the knockdown of any PNPLA. Since the
cells do not accumulate the phospholipids significantly (Table 1), this
result supports the notion that, beside turnover, the synthesis of PC,
PE and PS is inhibited in the cells depleted of PNPLA4, -6, or -9. The in-
hibition of synthesis is most likely indirect, i.e., it is due to a homeostatic
response to the reduced GPL degradation in the respective knockdown
cells.
To further assess the effect of thedepletion of PNPLA4, -6 or -9 on the
metabolism of PC we determined the specific labeling of the water-
soluble precursors of PC and its deacylation product GPC (Fig. S5). The
labeling of choline, phosphocholine and CDP-choline or GPC was only
modestly or insignificantly affected by the depletion of any of these
PNPLAs. The knockdown of PNPLA4, -6 or -9 slightly reduced the
labeling of phosphocholine and CDP-choline, consistently with the
Fig. 2. Effect of PNPLA depletion on synthesis of phospholipids. HeLa cells were treatedwith a control siRNA or siRNA targeting a PNPLA for 72 h andwere then incubatedwith D9-choline,
D4-ethanolamine, D3-L-serine and D6-myo-inositol for 24 h. The labeled and unlabeled lipids were quantified by LC-MS as described under Materials and methods and the labeled-to-
unlabeled ratios were plotted relative to that in the control cells. Data are mean of 3–5 independent experiments ± SD.
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served in the specific labeling of the PE precursors ethanolamine,
phosphoethanolamine and CDP-ethanolamine or the PS precursor ser-
ine (data not shown).
3.6. Effect of PNPLA depletion on cell growth
We consistently observed that the depletion of PNPLA9 resulted in a
markedly reduced number of cells per dish (up to 50% at 72 h of trans-
fection), while the depletion of PNPLA2, -3, -4, -6 or -8 had a somewhat
smaller effect on the cell number (~20% reduction). To assess whether
the lower cell number was due to a perturbed cell cycle, as suggested
previously for PNPLA9 [40], the cells were stained with propidium io-
dide and analyzed by flow cytometry. In the cells depleted of PNPLA9
or PNPLA4 (but not in those depleted of other PNPLAs) the cell cycle
was apparently perturbed as indicated by a ~30% decrease in the frac-
tion of cells in S/G2/M-phases (Supplemental Fig. S6). Consistently, the
expression of the proliferation marker MKI67 [37] was reduced by
~30% upon depletion of PNPLA4 and PNPLA9 (Supplemental Table S4).
These data suggest that a turnover of GPLs mediated by PNPLA9 or
PNPLA4 is required for a normal G1 to S cell cycle progression. Intrigu-
ingly, however, cell cycle was not impaired in the PNPLA6-depleted
cells despite that the turnover of GPLs was markedly inhibited in
those cells as well.
4. Discussion
4.1. PNPLAs are key mediators of GPL turnover in HeLa cells
Previous studies have shown that the turnover of PC is mainly
mediated by PLAs in many cell lines, including HeLa [8,15,41,42]. How-
ever, the particular PLAs involved in this process have remainedobscure. Herewe show that the depletion of PNPLA4, -6 and -9marked-
ly (30–50%) inhibited the turnover of PC as well as PE and PS in HeLa
cells. Consistent with the reduced turnover of PC and PE in the knock-
down cells, the amounts of GPC and GPE, the respective deacylation
products, were reduced by 30% in the cells that were depleted of
PNPLA9, -6 or -4. Complete cessation of the turnover of those GPLs
was not achieved, which could be due to incompleteness of PNPLA de-
pletion (Table S3), compensatory increases in non-targeted PNPLAs
(Fig. S2) or other phospholipases not studied here, or due to that no sin-
gle PNPLA is responsible for the degradation a GPL. To the latter option,
we attempted knocking down two PNPLAs simultaneously but, unfortu-
nately, such double knockdown was either inefficient or toxic to the
cells for unknown reasons. The fact that PNPLAs 4, 6, and 9, when
knocked down individually, had a clear effect on turnover PC PE and
PS suggests that collectively they probably account for most of the
extralysosomal turnover of those lipids.Whether these PNPLAs act indi-
vidually or in concert is not clear based on the current data, but appar-
ently their relative contributions vary depending on the GPL class. For
instance, PNPLA6 and -9 together may fully account for the turnover
of PS, while PNPLA4 seems to have only a minor role. On the other
hand, PNPLA4, -6 and -9 seem to contribute similarly to the turnover
of PC, PE andPEp. Presently it is not clear towhether the PNPLAs indicat-
ed in GPL turnover act as a PLA1, PLA2 or lysophopholipase in HeLa cells.
It is possible that they act either on different substrates within a class or
on different residues on the same substrates (e.g. sn1 or sn2 chain) and
the products are subsequently hydrolyzed by another PNPLA. The fact
that lysophopholipase activity of PNPLA6 is far higher than its phospho-
lipase activity in vitro [43] implies that this protein may act mainly as a
lysophopholipase in HeLa cells aswell. Consistently, we found that lyso-
PC accumulated 2.5-fold in the cells depleted of PNPLA6 (Table 1).
We emphasize that the present data by no means exclude the in-
volvement of other phospholipases in GPL homeostasis. It has been
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turnover of PC and PE in HeLa cells [44]. In the present study, the turn-
over of PI was not influenced by the knockdown of any PNPLA, which
suggests that PI turnover could bemediated by a PLC. Also the lysosomal
phospholipases most probably contribute to the degradation of cellular
GPLs, but their contribution is not clear at present.
Although abundantly expressed in HeLa cells (Fig. S1), the knock-
down of PNPLA2 or -3 had no significant effect on GPL turnover. This
is not unexpected since these enzymes have very low PLA-activity
in vitro and hydrolyze mainly TAGs [20]. PNPLA2 (a.k.a. ATGL) is proba-
bly themain TAG hydrolase inmammals [45]. Consistently, we find that
the knockdown of PNPLA2 in HeLa cells led to a 3-fold increase in their
TAG content (Table 1). In contrast, we did not observe an increase in
TAG content upon depletion of PNPLA3, consistently with that TAG
does not accumulate in the PNPLA3 knockout mouse [46].
PNPLA4 efficiently hydrolyzes TAGs and retinyl esters, but has a very
low PLA activity in vitro [20,47,48]. Thus it is intriguing that in the pres-
ent study the depletion of PNPLA4 had amajor impact on GPL turnover.
This may indicate that the protein requires some cofactors, e.g. other
proteins, lacking the in vitro studies, for an efficient hydrolysis of GPLs
in vivo. On the other hand, depletion of PNPLA4 markedly increased
the TAG content of HeLa cells (Table 1) consistently with the TAG hy-
drolase activity ascribed to this protein [20]. Whether the reduced GPL
turnover and TAG accumulation are linked is unclear, since TAG did
not accumulate in the cells depleted of PNPLA6 (Table 1).
Global knockout of PNPLA6 is embryonic-lethal in mouse [49] but
mice with a conditional knockout in the brain are viable [50]. These
mice exhibit elevated PC in the frontal cortex [51], which indicates the
role of PNPLA6 in PC homeostasis in this tissue. In HeLa cells, the knock-
down of PNPLA6 was shown to halve cellular GPC-content without af-
fecting steady-state PC-levels [52], consistently with the present study.
In neuronal cells of a PNPLA8 knockout mouse, cardiolipin was sig-
nificantly elevated, PEpwas depleted and themolecular species profiles
of several GPLswere altered [53], thus showing that PNPLA8 plays a cru-
cial role in GPL metabolism in neuronal cells of mouse. In the present
study, the metabolism of the major GPLs (cardiolipin was not studied)
was not perturbed upon the knockdown of PNPLA8. These contrasting
results could indicate that PNPLA8 participates in GPL homeostasis in
mouse but not in humans, or alternatively, its function may vary be-
tween cell types.
Consistent with the present data, early work on PNPLA9 suggested
that this enzyme could play a “housekeeping” role in mediating basal
PC turnover and generating lysophospholipid acceptors for incorpora-
tion of polyunsaturated fatty acids (e.g. arachidonate) to GPLs [14,21,
22,54], albeit not in all cell types [55]. On the other hand, PNPLA9 knock-
out mouse has neuronal problems [17,19], yet the GPL compositions of
its tissues are unaltered [56,57]. While this could be taken to indicate
that PNPLA9 is not involved in GPL homeostasis in mouse, it is possible
that this is not the case if coordination of synthesis and degradation
maintains the GPL composition constant. Besides greatly reducing GPL
turnover, depletion of PNPLA9 led to accumulation of TAG in the present
study (Table 1). It is not clear whether this is due to that PNPLA9 acts
also as a TAG hydrolase or because inhibition of PC and PE synthesis
(secondary to their diminished degradation) increases the concentra-
tion of diacylglycerol and, consequently, that of TAG. Intriguingly, ex-
pression of PNPLA2 doubled in cells depleted of PNPLA9 (Fig. S2),
which suggests that depletion of PNPLA9 could lead to a loss of TAG hy-
drolase activity which would (partially) be compensated by elevated
PNPLA2. Clearly, establishing whether this is the case requires further
experiments.
4.2. Effect on cell cycle
The cells depleted of PNPLA9 or PNPLA4 contained approx. 30% less
cells in S/G2/M phases (Supplemental Fig. S3) and the cell number per
plate was markedly reduced. Consistently, depletion of PNPLA9 hasbeen shown to inhibit the G1 to S transition, and to reduce the number
of cells per dish [40,58,59]. By which mechanism the depletion of the
PNPLAs affects the cell cycle or growth is not clear. However, as
PNPLA4 has been shown to facilitate transacylation of retinol and
accumulation of retinyl esters [48], the inhibition of the cell cycle
could be connected to retinol signaling that has been shown to inhibit
HeLa cell proliferation [60]. Interestingly, consistent with a previous re-
port [52], cell cycle appeared to proceed normally in the PNPLA6-
depleted cells despite a marked reduction in GPL turnover. This
indicates that the cell cycle progression is not directly coupled to GPL
turnover. Possibly, PNPLA9 and PNPLA4, but not PNPLA6, produces
lipid mediator(s) required for the cell cycle progression. Further inves-
tigations are required to resolve the mechanism by which PNPLA9 and
PNPLA4 promote cell proliferation.4.3. Coordination of GPL synthesis and degradation
Besides degradation, knockdown of PNPLA4, -6 and -9 inhibited the
synthesis of the major GPLs as indicated by a reduced labeling from a
head group precursor. Consistently, the level of phosphatidic acid, a pre-
cursor of all GPLs, was diminished in the knockdown cells (Table 1). Yet,
the inhibition of labeling of the different GPLs correlated with the inhi-
bition of their turnover (cf. Figs. 1 and 2), i.e., the synthesis decreased in
the order of PS N PC N PE N PEp while that of PI was unaffected. Consis-
tent with diminished PC synthesis, labeling of phosphocholine or CDP-
choline was also reduced in those knockdown cells. Together, these
data strongly support the previous results indicating that the synthesis
and degradation of GPLs are tightly coordinated in mammalian cells.
Such coordinationwould explainwhy the steady-state GPL composition
of HeLa cells did not change significantlywhen PNPLA4, -6 or -9was de-
pleted (Table 1).
While it is obvious that GPL synthesis and degradation must be
tightly coordinated in mammalian cells to maintain GPL homeostasis,
it is unclear how such coordination is achieved. It is possible that specific
regulator proteins sensing the GPL composition of cellular membranes
exist, and that such proteins regulate the homeostatic phospholipases
and synthetic enzymes. However, there is little if any experimental ev-
idence for such sensory proteins. It is also difficult to understand how
such proteins, if existing, would accurately “sense” the relative concen-
trations of the many different GPLs, as required to maintain homeosta-
sis, and howwould they relay this information to the enzymes carrying
out the synthesis and degradation so that these opposing process are ac-
curately coordinated. Regarding this, we have proposed a simple mech-
anism which could in principle accomplish such integration [2,30]. The
mechanism is based on the so-called superlattice (or regular distribu-
tion) model which suggest that different lipids tend to adopt regular,
rather than random lateral distribution in membranes [61,62]. From
this putative principle it necessarily follows that a limited number of
“critical” or optimal compositions with particular stoichiometries
exist. Another important prediction of the model is that when the com-
position deviates from a critical one, the molecules present “in excess”
would have an elevated chemical activity and, consequently, an in-
creased propensity to efflux from a membrane, which would make
them susceptible for hydrolysis by homeostatic PLAs. When the mole-
cules present in excess have been degraded, hydrolysis would stop or
slow down dramatically thus preventing excessive hydrolysis. Notably,
we have recently provided strong evidence that PNPLA9 is regulated by
substrate efflux propensity [63] and thus, potentially, by the tendency of
the membrane lipids to adopt regular distributions. Importantly, such a
tendency could also regulate the biosynthesis since the GPL molecules
present “in excess” should have increased chemical activity and could
thus potently inhibit the synthetic enzymes e.g. by a feedback mecha-
nism(cf. [61,62]). Accordingly, highly accurate coordination of synthesis
and degradation could be achieved by this simple mechanism based on
composition-dependent changes in the chemical activity of different
1064 M. Hermansson et al. / Biochimica et Biophysica Acta 1861 (2016) 1058–1065GPLs. However, further experimentation is required to assess the
validity of such putative homeostatic mechanisms.
In conclusion, the present data provide compelling evidence that
three PNPLA proteins play a key role in GPL degradation in HeLa cells.
It remains to be seen if those proteins play this role in other human
cells and tissues as well.
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